• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

FDA Clears Updated AI Software for Lung CT

News
Article

Reportedly offering improved delineation of pulmonary structures and greater accuracy with computed tomography (CT) values of pulmonary tissue, the artificial intelligence (AI)-powered LungQ 3.0.0. may facilitate enhanced precision and efficiency with interventional procedures such as lung volume reduction and ablation procedures.

The Food and Drug Administration (FDA) has granted 510(k) clearance for LungQ 3.0.0., an updated version of an artificial intelligence (AI)-enabled software platform for lung computed tomography (CT) scans, which is currently being utilized in more than 600 hospitals.

The enhanced software provides improved visualization and assessment of a variety of structures including lobes, subsegments and the most peripheral locations in the lungs to facilitate diagnosis and appropriate treatment of conditions such as emphysema and COVID-19, according to Thirona, the developer of LungQ 3.0.0.

FDA Clears Updated AI Software for Lung CT

The LungQ 3.0.0. software platform provides improved visualization and assessment of a variety of lung structures to facilitate improved outcomes with interventional lung procedures in addition to diagnosis and appropriate management of conditions such as emphysema and COVID-19, according to Thirona, the developer of the software.

Noting that the LungQ software platform has been validated in more than 200 publications globally, Thirona said the LungQ 3.0.0. software enhances the precision and efficiency of interventional procedures ranging from lung segmentectomy and ablation procedures to lung cancer biopsies and lung volume reduction.

“A clearer understanding of lung anatomy helps enable broader adoption of minimally invasive treatments for lung diseases such as COPD and lung cancer, helping save more healthy lung tissue and lung function capacity. … Solutions like LungQ are helping usher in a new era of personalized treatment for lung patients, enabling clinicians all over the world to conduct more advanced, easier-to-perform and less invasive procedures with full confidence,” said Eva van Rikxoort, the founder and CEO of Thirona.

Related Videos
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Nina Kottler, MD, MS
The Executive Order on AI: Promising Development for Radiology or ‘HIPAA for AI’?
Practical Insights on CT and MRI Neuroimaging and Reporting for Stroke Patients
Related Content
© 2024 MJH Life Sciences

All rights reserved.